Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study
Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study
复制标题
抗 Ro/SSA 抗体对类风湿性关节炎患者阿巴西普反应和保留的意义：一项多中心队列研究
DOI：
10.1080/03009742.2020.1772361
复制
发表时间：
2020
影响因子：
2.1
通讯作者：
Hi
中科院分区：
文献类型：
--
作者：
Endo Y;Koga T;Kawashiri S-Y;Morimoto S;Nishino A;Okamoto M;Tsuji S;Takatani A;Shimizu T;Sumiyoshi R;Igawa T;Iwamoto N;Ichinose K;Tamai M;Nakamura H;Origuchi T;Ueki Y;Yoshitama T;Eiraku N;Matsuoka N;Okada A;Fujikawa K;Hamada H;Tsuru T;Nagano S;Arinobu Y;Hi
目的：为了确定基线抗Ro/Sjögren综合征抗原A（SSA）抗体的阳性是否影响对阿巴西普的反应，我们使用多中心RA超声前瞻性队列比较了抗Ro/SSA抗体阴性和阳性的类风湿关节炎（RA）患者的治疗反应。我们回顾了2013年6月至2018年4月期间开始使用阿巴西普作为第一种生物疾病缓解抗风湿药物的日本RA患者。我们评估了接受阿巴西普治疗的RA患者基线与治疗后6个月或12个月之间的28关节疾病活动评分-红细胞沉降率（DAS 28-ESR）变化，以及6个月和12个月时的欧洲抗风湿联盟（EULAR）反应。全球OMERACT-EULAR滑膜炎评分（GLOESS）计算在基线和在6和12 months.Results：总体而言，51例患者入组，分为抗Ro/SSA抗体阴性和阳性组的35和16，分别。抗Ro/SSA抗体阴性组的基线中位年龄显著较高（p = 0.04）。抗Ro/SSA抗体阴性组12个月时的留存率和EULAR良好应答者百分比显著较高（均为p = 0.02）。在12个月时，抗Ro/SSA抗体阴性患者的DAS 28-ESR和DAS 28-C-反应蛋白降幅大于抗Ro/SSA抗体阳性患者（分别为p = 0.02和0.04）。抗Ro/SSA抗体阴性患者的GLOESS在6个月时显著降低（p = 0.03）。多因素分析显示，抗Ro/SSA抗体阳性是影响6个月DAS 28-ESR变化的独立因素（p < 0.05）。结论：抗Ro/SSA抗体阳性预示阿巴西普疗效差，留存率低。
Objective: To determine whether the positivity of baseline anti-Ro/Sjögren’s syndrome antigen A (SSA) antibodies influences the response to abatacept, we compared therapeutic responses between anti-Ro/SSA antibody-negative and -positive patients with rheumatoid arthritis (RA) using a multicentre RA ultrasonography prospective cohort.Method: We reviewed Japanese patients with RA who started abatacept as the first biological disease-modifying anti-rheumatic drug between June 2013 and April 2018. We assessed 28-joint Disease Activity Score–erythrocyte sedimentation rate (DAS28-ESR) change between baseline and 6 or 12 months after treatment in RA patients treated with abatacept, and European League Against Rheumatism (EULAR) response at 6 and 12 months. The Global OMERACT-EULAR Synovitis Score (GLOESS) was calculated at baseline and at 6 and 12 months.Results: Overall, 51 patients were enrolled and divided into anti-Ro/SSA antibody-negative and -positive groups of 35 and 16, respectively. Median age at baseline was significantly higher in the anti-Ro/SSA antibody-negative group (p = 0.04). The retention rate and percentage of EULAR good responders at 12 months were significantly higher in the anti-Ro/SSA antibody-negative group (both p = 0.02). Anti-Ro/SSA antibody-negative patients exhibited larger decreases in both DAS28-ESR and DAS28-C-reactive protein at 12 months than anti-Ro/SSA antibody-positive patients (p = 0.02 and 0.04, respectively). GLOESS decreased significantly at 6 months in anti-Ro/SSA antibody-negative patients (p = 0.03). Multivariate analyses showed that anti-Ro/SSA antibody positivity was an independent factor associated with change in the DAS28-ESR at 6 months (p < 0.05).Conclusion: Anti-Ro/SSA antibody positivity predicts a poor response to abatacept and low retention rate.